These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 33464021

  • 21. Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands.
    Bastiaans DE, Forcat S, Lyall H, Cressey TR, Hansudewechakul R, Kanjanavanit S, Noguera-Julian A, Königs C, Inshaw JR, Chalermpantmetagul S, Saïdi Y, Compagnucci A, Harper LM, Giaquinto C, Colbers AP, Burger DM, PENTA 18KONCERT Study Group.
    Pediatr Infect Dis J; 2014 Mar; 33(3):301-5. PubMed ID: 24356253
    [Abstract] [Full Text] [Related]

  • 22. Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood.
    Yang J, Nikanjam M, Best BM, Pinto J, Chadwick EG, Daar ES, Havens PL, Rakhmanina N, Capparelli EV.
    J Clin Pharmacol; 2018 Dec; 58(12):1604-1617. PubMed ID: 30252146
    [Abstract] [Full Text] [Related]

  • 23. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
    van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, Geerlings SE, Sutinen J, Ristola M, Danner SA, Reiss P.
    AIDS; 2009 Jul 17; 23(11):1367-76. PubMed ID: 19424051
    [Abstract] [Full Text] [Related]

  • 24. Effects of Combination Antiretroviral Therapy and Nutritional Rehabilitation on Growth in Children Aged 6-36 Months with Severe Acute Malnutrition in IMPAACT Protocol P1092.
    Mmbaga BT, Ngocho JS, Tierney C, Ziemba L, Reding C, Bone F, Bradford S, Costello D, Browning R, Moye J, Vhembo T, Mambiya S, Msowoya E, Owor M, Musoke P.
    J Pediatric Infect Dis Soc; 2024 Aug 24; 13(8):387-395. PubMed ID: 38808862
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana.
    Shapiro RL, Rossi S, Ogwu A, Moss M, Leidner J, Moffat C, Lockman S, Moyo S, Makhema J, Essex M, Capparelli E.
    Antivir Ther; 2013 Aug 24; 18(4):585-90. PubMed ID: 23183881
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults.
    Lamorde M, Byakika-Kibwika P, Boffito M, Nabukeera L, Mayito J, Ogwal-Okeng J, Tjia J, Back D, Khoo S, Ryan M, Merry C.
    J Acquir Immune Defic Syndr; 2012 Jul 01; 60(3):295-8. PubMed ID: 22481601
    [Abstract] [Full Text] [Related]

  • 29. Insulin sensitivity in multiple pathways is differently affected during zidovudine/lamivudine-containing compared with NRTI-sparing combination antiretroviral therapy.
    van Vonderen MG, Blümer RM, Hassink EA, Sutinen J, Ackermans MT, van Agtmael MA, Yki-Jarvinen H, Danner SA, Serlie MJ, Sauerwein HP, Reiss P.
    J Acquir Immune Defic Syndr; 2010 Feb 01; 53(2):186-93. PubMed ID: 19898246
    [Abstract] [Full Text] [Related]

  • 30. Are Prophylactic and Therapeutic Target Concentrations Different?: the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding.
    Foissac F, Blume J, Tréluyer JM, Tylleskär T, Kankasa C, Meda N, Tumwine JK, Singata-Madliki M, Harper K, Illamola SM, Bouazza N, Nagot N, Van de Perre P, Blanche S, Hirt D.
    Antimicrob Agents Chemother; 2017 Feb 01; 61(2):. PubMed ID: 27895016
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Clinical experience of raltegravir with abacavir/lamivudine or zidovudine/lamivudine in HIV-infected Korean adults.
    Kang SJ, An JH, Kim J, Jang MO, Kim SE, Park KH, Jung SI, Jang HC.
    Jpn J Infect Dis; 2013 Feb 01; 66(4):317-9. PubMed ID: 23883843
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Population Pharmacokinetics of Pediatric Lopinavir/Ritonavir Oral Pellets in Children Living with HIV in Africa.
    Chupradit S, Wamalwa DC, Maleche-Obimbo E, Kekitiinwa AR, Mwanga-Amumpaire J, Bukusi EA, Nyandiko WM, Mbuthia JK, Swanson A, DNDi Clinical TeamDrugs for Neglected Diseases Initiative, Geneva, Switzerland.Drugs for Neglected Diseases Initiative, Nairobi, Kenya.Drugs for Neglected Diseases Initiative, Bethesda, Maryland, USA., Cressey TR, Punyawudho B, Musiime V, LIVING Study Team.
    Clin Pharmacol Ther; 2024 May 01; 115(5):1105-1113. PubMed ID: 38247190
    [Abstract] [Full Text] [Related]

  • 38. Pharmacokinetics and 48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected patients.
    Ramautarsing RA, van der Lugt J, Gorowara M, Sophonphan J, Ananworanich J, Lange JM, Burger DM, Phanuphak P, Ruxthungtham K, Avihingsanon A.
    Antivir Ther; 2013 May 01; 18(2):249-52. PubMed ID: 22908131
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.